Revatio Injection Generic Name & Formulations
Mechanism of Action
Revatio Injection Indications
Pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and delay clinical worsening, in adults who are temporarily unable to take oral Revatio.
Revatio Injection Dosage and Administration
Give by IV bolus inj. 10mg three times daily.
Revatio Injection Contraindications
Revatio Injection Boxed Warnings
Revatio Injection Warnings/Precautions
Pulmonary veno-occlusive disease: not recommended. PAH secondary to sickle cell anemia (risk of vaso-occlusive crisis). Underlying conditions that could be affected by vasodilatory effects (eg, concomitant antihypertensive therapy, BP<90/50, fluid depletion, severe left ventricular outflow obstruction, autonomic dysfunction). Risk of non-arteritic anterior ischemic optic neuropathy; monitor for sudden vision loss. Retinitis pigmentosa: not recommended. Anatomical penile deformation. Predisposition to priapism. Severe hepatic impairment. Active peptic ulcer. Bleeding disorders. Elderly. Pregnancy. Nursing mothers.
Revatio Injection Pharmacokinetics
Mean absolute bioavailability: 41% (25–63%).
Maximum observed plasma concentrations are reached within 30–120 minutes (median 60 minutes) of oral dosing in the fasted state.
When taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%.
Mean steady state volume of distribution: 105 L.
Plasma protein bound: ~96%.
Fecal (~80%), renal (13%).
Revatio Injection Interactions
See Contraindications. Hypotension with nitrates. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir): not recommended. Antagonized by moderate to strong CYP3A4 inducers (eg, bosentan).
Revatio Injection Adverse Reactions
Headache, dyspepsia, flushing, pain in limb, myalgia, back pain, diarrhea; priapism, hypotension, vision or hearing loss.
Revatio Injection Clinical Trials
Revatio Injection Note
Revatio Injection Patient Counseling